<DOC>
	<DOC>NCT00127088</DOC>
	<brief_summary>This is a prospective phase II study of peri-operative docetaxel plus laparoscopic radical prostatectomy in patients with localized Gleason 7 pT2a-pT2b adenocarcinoma of the prostate and a risk of relapse after radical prostatectomy.</brief_summary>
	<brief_title>Study of Peri-Operative Docetaxel Plus Laparoscopic Radical Prostatectomy in Prostate Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Patients older than 18 years and less than 70 years Histologicallyproven Gleason 7 adenocarcinoma of the prostate pT2a or pT2b disease based on biopsies of the prostate More than 2/3 of positive biopsies or 15 ≤ serum PSA &lt;20 No previous carcinoma, except basalcell carcinoma of the skin Adequate renal function: measured or calculated creatinine clearance&gt; 60 ml/min Absolute granulocyte count ≥ 1,500/mm3, platelets ≥ 100,000 mm3, bilirubin ≤ 1.5 fold the upper normal value Signed informed consent. Patients infected by the Human Immunodeficiency Virus (HIV) Contraindication to general anesthesia or surgery Patients who do not fit inclusion criteria</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>Patients with localized Gleason 7 pT2a-pT2b adenocarcinoma of the prostate</keyword>
</DOC>